THE COST-EFFECTIVENESS OF ISOTRETINOIN IN PATIENTS WITH MODERATE-TO-SEVERE ACNE VULGARIS

被引：0
|
作者：
Shin, J. [1 ]
Hay, J. [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72709-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A146 / A146
页数：1
相关论文
共 50 条
  • [41] Treating patients with moderate-to-severe psoriasis vulgaris
    Kessler, Timothy R.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2022, 35 (03): : 28 - 35
  • [42] PSYCHOLOGICAL IMPACT OF THERAPY WITH ISOTRETINOIN IN MODERATE AND SEVERE ACNE PATIENTS
    Simic, D.
    Penavic, Zeljko J.
    Demirovic, H.
    ACTA DERMATO-VENEREOLOGICA, 2009, 89 (05) : 590 - 591
  • [43] Psychological Impact of Isotretinoin Treatment in Patients with Moderate and Severe Acne
    Simic, Dubravka
    Situm, Mirna
    Letica, Edita
    Penavic, Jasna Zeljko
    Zivkovic, Maja Vurnek
    Tomic, Teo
    COLLEGIUM ANTROPOLOGICUM, 2009, 33 : 15 - 19
  • [44] Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model
    Neyt, Mattias
    Stroobandt, Serge
    Obyn, Caroline
    Camberlin, Cecile
    Devriese, Stephan
    De Laet, Chris
    Van Brabandt, Hans
    BMJ OPEN, 2011, 1 (02):
  • [45] Safety and Efficacy of Low-Dose Isotretinoin in the Treatment of Moderate to Severe Acne Vulgaris
    Rao, Parinitha K.
    Bhat, Ramesh M.
    Nandakishore, B.
    Dandakeri, Sukumar
    Martis, Jacintha
    Kamath, Ganesh H.
    INDIAN JOURNAL OF DERMATOLOGY, 2014, 59 (03) : 316
  • [46] Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China
    Xu, Xinyi
    Geng, Linyu
    Xu, Xue
    Huang, Saisai
    Liang, Jun
    IMMUNOTHERAPY, 2024,
  • [47] COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Beilman, Candace L.
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2019, 156 (06) : S260 - S261
  • [48] Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis
    Wu, Jashin J.
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan
    Lowry, Simon
    Feldman, Steven R.
    Armstrong, April
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (07) : 693 - 700
  • [49] Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States
    Sullivan, Patrick W.
    Li, Qianyi
    Bilir, S. Pinar
    Dang, Joseph
    Kavati, Abhishek
    Yang, Ming
    Rajput, Yamina
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (01) : 23 - 32
  • [50] Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma
    Zafari, Zafar
    Sadatsafavi, Mohsen
    Marra, Carlo A.
    Chen, Wenjia
    FitzGerald, J. Mark
    PLOS ONE, 2016, 11 (01):
12345